Epigenos Bioscience Inc.

Epigenos Bioscience Inc. is a for-profit biotechnology company that develops novel gene therapy platforms by combining CRISPR/Cas9 technology with synthetic chemical epigenetic modifiers. The company aims to create targeted epigenetic therapeutics that can precisely upregulate or downregulate specific genes implicated in diseases like cancers and genetic disorders.

Through federal grant programs, Epigenos Bioscience has received funding to apply its proprietary CEMTROL technology towards optimizing transgene expression of adeno-associated virus (AAV) vectors for ocular gene therapies in collaboration with Dr. Matthew Hirsch. They were awarded $526,744 by the National Eye Institute to mitigate epigenetic dampening effects that can limit AAV transgene production. Additionally, the National Institute of General Medical Sciences provided $1,050,000 to develop a CRISPR/CEMTROL approach for locus-specific epigenetic activation of the TP53 tumor suppressor gene in preclinical colorectal cancer models as a means of sensitizing tumors to chemotherapy. Epigenos also received $251,236 from the National Center for Advancing Translational Sciences to leverage its chemical control of chromatin for treating Friedreich's ataxia, an inherited neurodegenerative disease. The diverse federal funding illustrates Epigenos Bioscience's efforts to advance targeted epigenetic gene regulation using its CEMTROL technology across multiple disease indications including cancers, genetic disorders, and gene therapy optimization.